Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
IOVA Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
33.30%
Analyst Rating:
BUY
Analyst Forecast (1yr):
190.20%
IOVA Stock Analysis
IOVA
PE Ratio:
IOVA
PEG Ratio:
Not Available
IOVA
Forward EPS Growth (12 month):
0.00%
IOVA
PS Ratio:
4.7
IOVA
PSG Ratio:
0.1
IOVA
Forward Revenue Growth (12 month):
38.70%
IOVA Articles
No data was found